Bunck, Mathijs C.

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 3,838

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,009

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1,005

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine

Obstructive Sleep Apnea ResearchPharmacology and Obesity Treatment

Cited by 871

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 860

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 792

Tirzepatide for Obesity Treatment and Diabetes Prevention

Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 462

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 442

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 388

Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone

Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology

Hormonal and reproductive studiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 349

Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience

Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008) · The Journal of Clinical Endocrinology & Metabolism

LGBTQ Health, Identity, and PolicyHormonal and reproductive studies

Cited by 308

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 240

Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men

van Raalte, D. H., Nofrate, V., Bunck, M. C., van Iersel, T., Elassaiss Schaap, J., Nässander, U. K., Heine, R. J., Mari, A., Dokter, W. H. A., & Diamant, M. (2010) · European Journal of Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 170

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 132

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m 2 : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

de Lemos, J. A., Linetzky, B., le Roux, C. W., Laffin, L. J., Vongpatanasin, W., Fan, L., Hemmingway, A., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024) · Hypertension

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 64

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes

Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 20

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · Diabetologie und Stoffwechsel

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 13

Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial: FR-OR47

Heerspink, H. J., Friedman, A. N., Bjornstad, P., Raalte, D. H. V., Yang, Z., Stefanski, A., Chigutsa, F. B., Turfanda, I., Bunck, M., & de Oliveira, C. P. (2023) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 3

0572 Weight reduction and the impact on apnea-hypopnea index: a meta-analysis

Malhotra, A., Curtis, A., Dunn, J., Bunck, M. C., & Bednarik, J. (2023) · SLEEP

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 2